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The introduction of next-generation sequencing
technologies has dramatically impacted the life sciences,
perhaps most profoundly in the area of cancer genomics.
Clinical applications of next-generation sequencing and
associated methods are emerging from ongoing large-
scale discovery projects that have catalogued hundreds
of genes as having a role in cancer susceptibility, onset
and progression. For example, discovery cancer genom-
ics has confirmed that many of the same genes are
altered by mutation, copy number gain or loss, or
structural variation across multiple tumor types, resulting
in a gain or loss of function that likely contributes to
cancer development in these tissues. Beyond these
frequently mutated genes, we now know there is a ‘long
tail’ of less frequently mutated, but probably important,
genes that play roles in cancer onset or progression.
Here, I discuss some of the remaining barriers to clinical
translation, and look forward to new applications of
these technologies in cancer care.types of somatic alterations that drive cancer develop-
ment [6]. Importantly, not only can rapid DNA sequen-Introduction
In 2004, following the completion of the Human Genome
Project [1], a correlation was described between a specific
set of mutations and patients whose lung cancers had
dramatically responded to a new class of therapeutics called
tyrosine kinase inhibitors (TKIs) [2]. Our group and two
others [2-4] found that about 80% of patients with a
response to a TKI carried somatic mutations in the gene
encoding the epidermal growth factor receptor (EGFR)
resulting in changes to the amino acid sequence. Those
efforts involved low-throughput technology that combined
PCR amplification of the EGFR exons with fluorescent
capillary electrophoresis-based sequencing, and yet were
revealing in that they linked a specific gene and itsCorrespondence: emardis@wustl.edu
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Exciting as these discoveries were just 8 years ago, today
the first-line therapy and standard of care for non-small-
cell lung cancer patients with mutated EGFR is to prescribe
a TKI. While these mutations occur in only about 10% of
lung adenocarcinoma patients, subsequently other genes
with corresponding targeted therapies have been identified
in lung cancer. Furthermore, a large number of driver
alterations have been identified in lung adenocarcinoma, a
significant proportion of which can be treated with specific
drug-gene combinations, and there are many more drivers
to be identified [5].
In the ensuing 8 years, DNA sequencing technology
has taken a dramatic and welcome turn away from those
expensive and slow methods of 2004, to so-called ‘next-
generation’ or ‘massively parallel’ technologies that can
deliver DNA sequencing data for a complete human
genome overnight. The result of this technology acceler-
ation, and the accompanying types of sophisticated ana-
lyses that can be applied to cancer genome data, have
transformed our understanding of the numbers and
cing now quickly identify mutated genes, but these can
be matched to increasing numbers of protein-targeted
therapies, creating a virtuous circle that is beginning to
revolutionize clinical cancer care. However, there are
issues that complicate the application of our new know-
ledge to the care of cancer patients. These issues revolve
around the difficulties of adding new methods to already
established standards of care in medicine, the need to
train physicians across the cancer care discipline regard-
ing how best to apply these new data to clinical practice,
and how to make the enhanced information from
genomics ‘fit’ into a drug approval process that has, until
now, only dealt with drugs targeting single disease sites.Debatable issues for translation
A multitude of questions remain unanswered in the
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how comprehensively the cancer genome should be
characterized to identify mutated genes that may result in
response to a drug, to more social issues regarding
physician education and sharing of results. One important
question is whether to test only a small number of
‘druggable’ genes for mutations (a panel), or to take an
unbiased look across the exome (the DNA sequence of
the exons of all known genes in the genome), or to
sequence the whole genome. Although the latter is most
expensive and time-consuming, whole-genome data can
be mined for the multitude of alterations that commonly
occur in cancer genomes, including structural variants
such as chromosomal translocations, large-scale rear-
rangements and deletions that often fuse exons to create
new fusion proteins. Sequencing the exome or a smaller
gene list provides a reduced view of the somatic landscape,
has limited capability to capture structural variants, and
omits regions such as known promoters or other regula-
tory regions (for example, the TERT gene promoter, a
recently discovered mutated driver in melanoma and
other tumor types [7,8]). Obviously, the fewer the number
of genes studied, the more inexpensive the assay and the
more rapid the analysis. In this scenario, however, genes
with potential therapeutic indications, such as those in the
same biological pathway as a druggable gene that is not
itself mutated, will be missed. Hence, a proportion of
patients will not obtain a therapeutic match owing to the
limited scope of a panel test.
Unfortunately, the complexity of whole-genome analysis,
the cost of data generation, and the need for analysis and
interpretation to happen in a clinically relevant timeframe
have limited the scaling of this most comprehensive
approach to high throughput. Our current approach is to
sequence the whole genomes of tumor and normal tissue,
and to perform exome sequencing of tumor and normal
tissue, supplementing the exome capture reagent with
additional probe sets that enhance the coverage of
frequently mutated genes. This integrated approach
improves our ability to detect known variants while not
eliminating our ability to discover new variants as well.
A related issue that reflects the difference between
PCR-based and massively parallel sequencing (MPS)
involves the sequencing of matched normal tissue from
the patient. In the existing clinical assay paradigm, only
hotspot mutations (such as those discussed earlier in the
EGFR tyrosine kinase domain) are sequenced from
tumor tissue only. No matching normal tissue is se-
quenced because these mutations are typically only
present in cancer cell genomes, and because the assays
are quite focused in their scope, detecting mutations
only in restricted, commonly mutated regions. By con-
trast, the broader scope and ease of obtaining MPS data
have changed the focused nature of these assays,resulting in the detection of all variants, somatic and
germline, from tumor DNA. Hence, the comparator nor-
mal sequence is critically important to define precisely
which variants are somatic, but including the normal
tissue doubles the cost of sequencing and disrupts the
existing clinical assay paradigm. Further complications
arise from the broad scope of MPS inquiries because
novel mutations in cancer genes are identified (not just
the hotspots), often with no clear indication of their
pathogenicity (that is, gain or loss of function) or their
likely drug response.
Another issue involves a second data type that is pro-
ving to be critically informative but is not presently being
utilized by most diagnostic testing assays: RNA sequen-
cing of the tumor. RNA sequence data can provide an
incredible range of information that identifies genes that
are aberrantly overexpressed (often without any indication
from DNA sequence data, such as copy number amplifica-
tion), alleles that are mutated in DNA and potentially
druggable, yet are silenced in RNA (again, often without
DNA evidence for silencing), and fusion transcripts [9]. In
the clinical setting, it is important to detect overexpression
of a ‘driver’ RNA owing to the potential for drug targeting
(for example, HER2 in breast cancer), and often the poten-
tial for overexpression cannot be detected simply through
the examination of DNA (for example, when overexpres-
sion is due to altered methylation or histone binding).
Furthermore, the support provided by RNA sequence data
for analysis of detected DNA variants provides confirm-
ation of potentially druggable mutations. One difficulty in
interpreting overexpression lies with the fact that a com-
prehensive database of RNA expression from RNA
sequencing of normal human tissues does not presently
exist, although there are efforts to produce such a data-
base (for example, GTEx [10]). When possible, adjacent
non-malignant tissue may be sequenced to establish aber-
rant expression levels in the tumor by comparison. Ultim-
ately, although RNA sequencing represents additional
expense and effort, it should enhance our ability to find
more answers for more patients [11]. We presently
include RNA sequencing of the tumor in our sequencing-
based approach to detecting druggable alterations.
Heterogeneity across the cancer cell genomes in each
patient’s tumor is just beginning to be understood at the
level of DNA [12-14]. The sensitivity to detect heteroge-
neous cancer genomes is enhanced by the digital nature
of NGS and may eventually provide prognostic informa-
tion (for example, if more heterogeneous tumors are
found to be more likely to acquire therapeutic resistance
or to metastasize). Although some studies have pre-
dicted that heterogeneity may also imply that therapeutic
response in patients with multiple metastatic sites will
be unsuccessful [12,15], it remains to be seen whether
novel, metastasis-specific mutations are common in all
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metastasis. Furthermore, an ultimate aim of translating
cancer genomics to clinical care should be to include
sequencing-based diagnostic assays at first diagnosis
rather than in the advanced disease setting. In this way,
current concerns about the complexity of metastatic
presentation could well be obviated if the clinical
efficacy of precision cancer therapeutics was successful
at primary disease presentation. This practice would also
enable the detection of recurrent disease or therapeutic
resistance with higher sensitivity than provided by avail-
able imaging technologies, using blood-based monitor-
ing, as discussed below.
Educational issues remain and must be addressed if
physicians are expected to order, understand and act upon
diagnostic results obtained from NGS data. These issues
are more readily addressed for physicians in training, and
most top-tier medical schools are already offering first-
year students an introduction to genomic medicine con-
cepts, as well as specialized residency training programs in
translational genomics. However, the larger number of
practicing physicians who also want to use genomics-
based diagnostics but feel alienated because they do not
understand the approach and how best to interpret the
results of data analysis will need effective continuing
medical education (CME)-based training and user-friendly
decision support tools to feel sufficiently educated and
confident to order and interpret these tests. Furthermore,
they will need evidence that specific gene-mutation-
targeted therapy combinations will provide clinical bene-
fits, which may be challenging to demonstrate with the
current paradigm of one-size-fits-all clinical trials.
A final issue for debate is that no rapid and straight-
forward mechanism currently exists to communicate the
results of what are essentially single-patient studies,
often referred to as ‘N of 1’. In essence, early efforts that
use NGS diagnostics to aid in therapeutic decision-
making will be experimental and will often involve single
patients. Analytical and interpretational pipelines will
determine which targeted therapies are most likely to
benefit each patient, and in the cases where a patient is
treated with a targeted therapy and is monitored to
evaluate their response, we need a reporting mechanism
that can serve to effectively communicate these results
to all groups engaged in this enterprise. This type of
reporting must include sharing of those cases for which
all indications pointed to a specific therapy yet the
patient did not achieve a response. Although the typical
reporting of case studies occurs through a peer review
process, the need for data sharing in this realm is too
urgent to wait for the time required to write and publish
a manuscript, and the numbers of cases too large to
report each one in this manner. Reporting cases from
N of 1 studies in an accessible, community-friendlydatabase format will ensure that each patient’s diagnosis
and treatment will be as informed as possible. A
BioRΧiv-like pre-print server [16] may be worth consi-
dering as a vehicle for communication of results. The
acquired data from such an exercise would still need to
be organized for rapid analysis of new patient data; this
is perhaps best funded by the National Institutes of
Health (NIH) to ensure free and open access to data
while maintaining precautions about data privacy. Those
who report cases to the database would have an obliga-
tion to follow up on patient outcome data, ensuring
maximum benefit. Only as a community willing to share
openly will we effectively build the case for the clinical
efficacy of genome-guided therapy decisions.
Practical barriers to translation
There are four main areas that are practical barriers to
the successful translation of NGS-based diagnoses for
cancer. These relate to tissue preparation methods and
their impact on nucleic acids, the limited amount and
availability of clinical samples for genomic study, and
the clinical trials paradigm - as it affects the approval
and availability of targeted therapies. Chief among these
is the established practice of preserving tissues in forma-
lin and paraffin. Formalin is problematic because it
causes nucleic acid degradation by crosslinking to both
DNA and RNA backbones, an effect that is worsened by
storage time. There are other preservatives besides
formalin, such as HOPE or PAXgene, that are commer-
cially available and are less damaging to nucleic acids
while maintaining tissue morphology for microscopic
assays. However, supplanting the standard pathology
preparatory method of formalin fixation and paraffin
embedding is unlikely in the near term because it has
been the standard in pathology for over 100 years.
Perhaps the best driver of this change would be the
widespread use of NGS methods in the diagnostic
laboratory. For the time being, methods to determine the
extent of degradation of DNA or RNA isolated from for-
malin/paraffin-preserved samples isolated from a tumor of
interest are critical precursors to determine whether these
nucleic acids are appropriate for NGS.
Often, in addition to the problems associated with
formalin fixation and paraffin embedding, the amount of
tissue that is available for nucleic acid isolation is
limited. After all, the biopsy will also be needed for
conventional diagnostic tests, so it needs to be shared
across multiple tests for comprehensive diagnosis. The
availability of only low amounts of input nucleic acid is
common, and methods tailored to low-input library
generation prior to NGS are required. In reality, the
combination of formalin/paraffin preservation and low
input is quite common, so robust protocols must be
designed for the combination of these two limiting
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is that multiple genes can be studied in a single assay, in
contrast to PCR-based assays that evaluate one gene hot-
spot at a time. With PCR, multiple assays are required
to test multiple genes in hopes of identifying a thera-
peutic match, and if insufficient material is available to
run multiple assays, a best guess at which genes are
most likely mutated is required.
Radiation therapy and some chemotherapeutic agents
damage DNA, and all therapies profoundly influence the
genomic heterogeneity of any recurrent or metastatic
tumor. As a result, for patients who have failed first- or
second-line therapy for their tumor type, a new tumor
biopsy must be obtained for genomic studies because
the genomic profile of the tumor is likely to have been
altered by therapeutic intervention. In a few tumor
types, the repeat sampling of metastatic or recurrent
disease is straightforward, as it is the standard of care
and/or is covered by insurance. Far too often, however,
repeat sampling is neither the standard of care nor
straightforward (for example, for bone or brain metasta-
ses), thereby significantly complicating the ability to
assay recent tumor samples to identify new therapeutic
targets. New approaches to blood-based monitoring of
tumor DNA or cells may help to address these issues, as
discussed below.
The fourth practical issue is frequently encountered
with NGS-based assays. NGS data often predict that a
therapy not approved by the US Food and Drug Admin-
istration (FDA) or similar governmental bodies for use
in that particular tumor type will be effective. This result
reflects the growing data from large-scale genomic dis-
covery projects that show that genes that are frequently
mutated in cancers are largely not specific for the tissue
type of the tumor [17,18]. Although tissue biology
remains important for understanding tumor pathology
and drug response, the same somatically altered genes
can be initiators of oncogenesis in different tissue types.
Hence, a new paradigm for clinical trials of antineoplas-
tic drugs has emerged that hopefully will feed forward
into the FDA approval process. One such type of trial is
the ‘basket’ trial, in which the gene(s) targeted by a
specific drug are tested across patients with multiple
disease sites (for instance, lung, colon, breast) and only
those patients with a mutational profile suggestive of a
therapeutic response are included in the trial [19]. This
approach can enable more rapid trial closure or acceler-
ation than trials focusing on a specific disease site,
depending upon patient response rates, and could per-
mit FDA consideration of a drug for approval in multiple
disease sites [20]. Another trial type is the ‘umbrella’ or
‘master protocol’ trial, in which a collection of targeted
therapies and corresponding NGS-based molecular
profiling companion diagnostic assays are combined totreat either a single cancer type or multiple cancer types
[21]. There are numerous examples of basket and umbrella
trials being conducted by pharmaceutical companies, the
NIH (such as NCI-MATCH), and by hospital systems
(for example, Princess Margaret Hospital’s IMPACT trial
[22]).
Promising new translational approaches
As frequently occurs with emerging technology, innova-
tive approaches that address several of the aforementioned
issues are rapidly coming onto the scene. For example, in
the case of acquired resistance to therapy, earlier detection
is critical to permit the oncologist to devise a new thera-
peutic regimen before metastatic disease is too advanced.
However, metastatic disease is often detected too late by
imaging technologies that require a tumor mass to achieve
a minimal size before it can be detected. New efforts are
pursuing the early detection of circulating tumor cells
(CTCs) or circulating DNA or RNA [23], often using NGS
to characterize the initial disease presentation, so that
mutated genes are identified for that patient’s disease and
can then be detected by less expensive, more rapid assays
using blood samples, taken at strategic time points after
surgery to remove the tumor [24,25]. As the genomic
alterations that emerge in resistance to targeted therapies
are better understood [26-28], these also may be moni-
tored by specific blood-based assays. Another example of
an application for CTC- or circulating nucleic-acid-based
monitoring is in prostate cancer. This approach is cur-
rently being used to monitor the progression to androgen-
resistant disease, which typically forms metastases in bone
[29,30]. However, the approach could also be used as a
means of informing active surveillance for men with a
prostate cancer diagnosis but low risk of developing aggres-
sive disease.
The basket and umbrella clinical trial designs will
identify more cases of ‘extreme responses’ to targeted
therapies, defined as those patients whose tumor burden
is alleviated rapidly (complete remission) and, in some
cases, with long duration [31]. Comprehensive genomic
studies of these patients may add genes to the repertoire
of diagnostic assays that predict the likelihood of
extreme response, and thus better inform therapeutic
decision-making. A related consequence of genomic
testing for therapy selection is the likely transition of
companion diagnostics to sequence-based tests, rather
than slower, less sensitive and less specific assays such as
fluorescent in situ hybridization (FISH) or cytogenetics.
As a result, more patients will be correctly identified as
candidates for the drugs that are most likely to help
relieve their disease burden.
One interesting application of NGS may amplify the
resurgence of immunotherapies, which is currently being
driven by the antineoplastic properties of the new
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system’s interaction with cancer cells [32-36]. In a new
paradigm, NGS identifies tumor-specific mutations and
their RNA expression levels, and these data are used to
predict immunoepitopes for vaccine development,
ignoring the druggable targets and instead prioritizing
those tumor-unique peptides that are most immune-
stimulatory, for use in vaccine development [37,38]. An
algorithmic method for prediction of class I human
leukocyte antigen (HLA) binding affinity considers the
highly expressed somatic missense (altering the amino
acid sequence) mutations discovered by NGS analysis,
and provides scores for the binding affinity of mutant
neoantigens compared with their corresponding wild-
type protein sequences [39]. Various in vitro tests using
patient-derived T cells can further refine the list of
candidates for use in personalized vaccine development,
to provide a final list of the most immune-stimulatory
peptide sequences that are unique to a patient’s tumor.
A variety of approaches can be considered for producing
a patient-specific vaccine, such as a multivalent DNA
vaccine that includes the prioritized peptide-encoding
sequences in a vaccine vector, or a dendritic-cell vaccine
that uses patient-specific peptides to stimulate the
patient’s own dendritic cells to induce T-cell memory
[37]. Furthermore, the astounding sequencing capacity of
NGS instruments now makes monitoring changes in a
patient’s T- and B-cell repertoires quite straightforward
within a single experiment [40], and could provide a critic-
ally important component of patient monitoring during
immunotherapy or other therapeutic interventions.
Conclusions and future directions
Multiple technological innovations fueled by the appli-
cation of NGS technology to cancer genomics are now
making the clinical use of NGS platforms and assays
increasingly common. Applications for therapeutic
decision-making, including for new clinical trials of
targeted therapies, are increasing the demand for NGS
assays and improving cancer care and patient monitor-
ing. Over coming years, this virtuous circle will provide
important metrics that establish the sensitivity and
specificity of NGS-based diagnostic assays in comparison
to current clinical standards (for example, FISH or
immunohistochemistry). These efforts will also consoli-
date the use of NGS-based diagnostics in cancer medi-
cine by virtue of clinical efficacy, as the precision
afforded by these tests results in patient relief from
disease burden by prescribing the right drug for each
patient’s disease. The associated disruption caused by
these diagnostic changes will affect current pathology-
based diagnoses, challenge standards of care for most
cancer types, and invoke the many other issues discussed
here. Ultimately, this disruption and the resolution ofthese issues will benefit patients by ensuring more
precise diagnostic and therapeutic results in their fight
against cancer.
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